Loading company…
Berlin-based biotech developing antibody-based cancer therapies that target tumour-associated carbohydrate antigens.
Founded in 2019 by co-founder and CSO Peter Sondermann, Tacalyx GmbH is a Berlin-based biotechnology company developing antibody-based cancer therapies. Its pipeline includes antibody-drug conjugates and T cell engagers targeting tumour-associated carbohydrate antigens in solid tumours. In April 2026 the company raised EUR 11 million in Series A funding from Boehringer Ingelheim Venture Fund, Kurma Partners, High-Tech Gründerfonds, Eurazeo, Creathor Ventures, and Thuja Capital, as part of a EUR 25 million Series A. Jean Engela is CEO.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in